Financial Performance - Net revenues for Q1 2025 were $220,972,000, a 19% increase from $185,600,000 in Q1 2024[26] - Operating expenses totaled $214,303,000 in Q1 2025, up from $189,632,000 in Q1 2024, reflecting an increase of 13%[26] - The company reported an income from operations of $6,669,000 in Q1 2025, compared to a loss of $4,032,000 in Q1 2024[26] - Net loss attributable to GoHealth, Inc. was $4,408,000 in Q1 2025, an improvement from a net loss of $9,216,000 in Q1 2024[26] - The net income (loss) per share for Class A common stock was $(0.52) in Q1 2025, compared to $(1.04) in Q1 2024[26] - Comprehensive loss for Q1 2025 was $9,905,000, an improvement from a comprehensive loss of $21,351,000 in Q1 2024[30] - For the three months ended March 31, 2025, GoHealth reported a net loss of $9,786 thousand, compared to a net loss of $21,346 thousand for the same period in 2024, indicating a 54.2% improvement in net loss year-over-year[39] - Adjusted EBITDA for Q1 2025 was $42.060 million, a 56.4% increase from $26.894 million in Q1 2024, with an adjusted EBITDA margin of 19.0%[165] Assets and Liabilities - Total assets decreased to $1,382,067,000 as of March 31, 2025, down from $1,488,423,000 at the end of 2024[32] - Cash and cash equivalents decreased to $22,153,000 as of March 31, 2025, from $40,921,000 at the end of 2024[32] - Current liabilities decreased to $233,399,000 as of March 31, 2025, compared to $338,052,000 at the end of 2024[32] - The company had a total stockholders' equity of $397,086,000 as of March 31, 2025, down from $405,438,000 at the end of 2024[32] - As of March 31, 2025, the total long-term debt of the company is $446.4 million, a slight decrease from $447.9 million as of December 31, 2024[62] - The company reported a net cash used in operating activities of $12,405 thousand for Q1 2025, compared to net cash provided of $12,512 thousand in Q1 2024[39] - The company raised substantial doubt about its ability to continue as a going concern due to insufficient funding to meet obligations within the next twelve months[214] Revenue Sources - Medicare revenue increased to $219.404 million in Q1 2025, up 18.5% from $185.026 million in Q1 2024, driven by a significant rise in agency revenue[100] - Agency revenue, which includes commission revenue and partner marketing, reached $187.633 million in Q1 2025, a substantial increase of 89.4% compared to $99.124 million in Q1 2024[100] - The increase in net revenues was primarily driven by an $88.5 million rise in agency revenue, partially offset by a $54.1 million decrease in non-agency revenue[147] - The Company recognized $41.6 million in revenue from deferred revenue during Q1 2025, compared to $34.9 million in Q1 2024[110] Expenses - Share-based compensation increased to $2,803 thousand in Q1 2025 from $1,783 thousand in Q1 2024, reflecting a 57.0% increase[39] - Marketing and advertising expenses rose to $67.415 million in Q1 2025, a 27.7% increase from $52.775 million in Q1 2024, aimed at generating more qualified prospects[149] - General and administrative expenses increased by 33.9% to $22.656 million in Q1 2025, primarily due to costs associated with the e-TeleQuote acquisition[153] - Interest expense decreased to $15.954 million in Q1 2025 from $17.951 million in Q1 2024, reflecting a reduction in interest rates on the Term Loan Facility[155] Operational Changes - The company is currently in compliance with its financial covenants but faces substantial doubt about its ability to continue as a going concern due to potential liquidity constraints[50] - The company has developed mitigating plans to address potential liquidity constraints, including cost control measures and renegotiation of existing debt arrangements[50] - The company is actively looking to terminate or sublease certain office spaces and call centers as part of its cost savings initiatives[60] - The company completed the acquisition of e-TeleQuote on September 30, 2024, and excluded it from the internal control evaluation for the quarter ended March 31, 2025[207] Customer Engagement - Submissions increased to 303,026 in Q1 2025 from 216,148 in Q1 2024, indicating a significant growth in customer engagement[168] - For the three months ended March 31, 2025, the number of Submissions increased to 303,026, up 40.2% from 216,148 in the same period of 2024, primarily due to enhanced marketing efforts and increased agent headcount following the e-TeleQuote acquisition[170] Legal and Compliance - The company is contesting a derivative action related to alleged breaches of fiduciary duty, which may impact its financial condition[120] - The company is subject to various legal proceedings that could adversely affect its business and financial condition[213] - The company’s internal control over financial reporting was evaluated as effective as of March 31, 2025[205]

Core Insights - GoHealth Inc. (NASDAQ: GOCO) reported a strong performance in Q1 2025, with net revenues increasing by 19.1% year-over-year to $221.0 million, driven by a significant rise in submissions [1][7] - The company achieved an operating income of $6.7 million, a notable improvement from the previous year's loss, and Adj. EBITDA grew by 56.4% to $45.1 million, highlighting operational efficiencies [1][7] - GoHealth's growth is attributed to its leadership in the Medicare-focused digital health marketplace, supported by strategic investments in technology and operational excellence [1] Financial Performance - Q1 2025 net revenues reached $221.0 million, up from $185.6 million in the same period last year, reflecting a 19.1% increase [7] - The number of submissions in Q1 2025 was 303,026, representing a 40.2% increase compared to 216,148 submissions in Q1 2024 [7] - The company launched GoHealth Protect during the quarter, indicating a focus on innovation and market expansion [7]

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GoHealth, Inc. (“GoHealth” or the “Company”) (NASDAQ: GOCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether GoHealth and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 1, 2025, th ...

分组1 - GoHealth reported a quarterly loss of $0.47 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.26, but an improvement from a loss of $0.89 per share a year ago, indicating an earnings surprise of -80.77% [1] - The company posted revenues of $220.97 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.77%, but showing an increase from year-ago revenues of $185.6 million [2] - GoHealth shares have declined approximately 39.3% since the beginning of the year, contrasting with the S&P 500's decline of -0.6% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$1.78 on revenues of $120.77 million, and for the current fiscal year, it is -$2.04 on revenues of $862.42 million [7] - The Zacks Industry Rank for Insurance - Life Insurance is currently in the top 31% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]

Financial Data and Key Metrics Changes - Q1 2025 revenue increased to $221 million, a 19% improvement from $186 million in Q1 2024 [9][26] - Adjusted EBITDA for Q1 2025 grew to $42.1 million, representing a 56% increase from $26.9 million in Q1 2024 [26] - GAAP net loss for the quarter was $9.8 million, showing significant year-over-year improvement [26] - Cash flow from operations reported a negative $12.4 million, down from a positive $12.5 million in the prior year [27] Business Line Data and Key Metrics Changes - Submission volume in Q1 increased significantly, driven by a 64% year-over-year growth in the captive Medicare team, while agent headcount grew by only 24% [9][10] - Sales per submission decreased by 15% year-over-year, attributed to a higher mix of agency versus non-agency submissions [11][52] Market Data and Key Metrics Changes - CMS announced a 5.06% average increase in Medicare Advantage revenue for health plans and a 10.72% increase in the Broker Commission Schedule, marking the most significant adjustment in over a decade [21] - The company anticipates a disruptive Annual Enrollment Period (AEP) due to health plans suppressing commission eligibility and adjusting plan benefits [22][23] Company Strategy and Development Direction - GoHealth is transitioning from a traditional Medicare enrollment company to a Medicare engagement company, focusing on long-term relationships with consumers [7][8] - The launch of GoHealthProtect, a suite of life insurance products, aims to diversify the product portfolio and reduce revenue seasonality [12][16] - Continued investment in technology and AI tools is expected to enhance consumer experience and agent efficiency [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the market conditions but acknowledged the uncertainty surrounding health plan decisions and their impact on growth [23][30] - The company plans to leverage GoHealthProtect to stabilize revenue and cash flow during the second and third quarters [59] Other Important Information - GoHealth is facing a lawsuit related to alleged violations of the False Claims Act and the Anti-Kickback Statute, which the company intends to vigorously defend [23][25] - The company reported a significant increase in commissions receivable, growing nearly 19% year-over-year, indicating the durability and scale of the business [27] Q&A Session Summary Question: Opportunities to improve capital structure - Management indicated ongoing assessment of capital structure alternatives, emphasizing the importance of timing and terms to enhance their position [37][38] Question: Thoughts on United's changes and expectations for AEP - Management noted industry-wide margin challenges and anticipated more benefit resets and disruptions in the upcoming AEP [39][42] Question: Details on GoHealthProtect and marketing strategy - Management clarified that GoHealthProtect is being tested with a consumer-oriented approach, balancing outbound and inbound marketing strategies [45][48] Question: Explanation of sales per submission decline - Management explained the decline is due to a mix shift between agency and non-agency contracts, not a change in isolated rates [52][53] Question: Growth from eTeleQuote agents - Management stated that integration with eTeleQuote agents is ongoing, contributing to a 25% year-over-year increase in agent headcount [57] Question: Balance sheet information - Cash at the end of the quarter was $23 million, down from year-end figures [62]

Financial Data and Key Metrics Changes - Q1 2025 revenue increased to $221 million, a 19% improvement from $186 million in Q1 2024 [7][25] - Adjusted EBITDA for Q1 2025 grew to $42 million, representing a 56% year-over-year increase from $26.9 million in Q1 2024 [7][27] - GAAP net loss for the quarter was $9.8 million, showing significant improvement year-over-year [26] - Cash flow from operations reported a negative $12.4 million, compared to a positive $12.5 million in the prior year [27] Business Line Data and Key Metrics Changes - Submission volume in Q1 increased year-over-year, driven by a 64% growth in the captive Medicare team, while agent headcount grew by 24% [7] - Sales per submission decreased by 15% year-over-year, attributed to a higher mix of agency versus non-agency submissions [10][51] Market Data and Key Metrics Changes - CMS announced a 5.06% average increase in Medicare Advantage revenue for health plans and a 10.72% increase in the Broker Commission Schedule [20] - The company anticipates a disruptive Annual Enrollment Period (AEP) due to health plans suppressing commission eligibility and adjusting plan benefits [21] Company Strategy and Development Direction - GoHealth is transitioning from a traditional Medicare enrollment company to a Medicare engagement company, focusing on long-term relationships with consumers [6] - The launch of GoHealthProtect, a suite of life insurance products, aims to diversify the product portfolio and reduce revenue seasonality [11][15] - Continued investment in technology and AI tools to enhance consumer experience and agent efficiency [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming AEP despite potential disruptions, indicating a need for consumers to reassess their options [21][22] - The company is focused on capital discipline and maximizing return on investment while adapting to evolving market dynamics [30] Other Important Information - GoHealth is involved in a key lawsuit related to alleged violations of the False Claims Act and the Anti-Kickback Statute, which the company intends to vigorously defend [22][23] Q&A Session Summary Question: Opportunities to improve capital structure - Management indicated ongoing assessment of capital structure alternatives and emphasized that DOJ actions would not deter plans to enhance capital efficiency [38][39] Question: Thoughts on United's changes and expectations for AEP - Management noted industry-wide margin challenges and anticipated more benefit resets and disruptions in the upcoming AEP [40][42] Question: Details on GoHealthProtect offering and marketing strategy - Management clarified that GoHealthProtect is being tested with a consumer-oriented approach and selective partnerships, with a balanced marketing strategy [45][48] Question: Explanation of sales per submission decline - Management explained that the decline is due to a mix shift between agency and non-agency contracts, not a change in isolated rates [51][52] Question: Growth from eTeleQuote agents - Management stated that integration with eTeleQuote agents is ongoing, contributing to a 25% year-over-year increase in agent headcount [58] Question: Balance sheet information - Cash at the end of the quarter was $23 million, down from year-end [63]

Financial Performance - GoHealth's Q1 2025 revenue increased to $221 million, a 19% increase compared to $1856 million in Q1 2024[11] - Adjusted EBITDA for Q1 2025 was $421 million, a 56% increase from $269 million in Q1 2024[11] - Cash flow from operations improved significantly, from -$124 million in Q1 2024 to $125 million in Q1 2025, a 199% increase[14] - Ending commissions receivable (current and non-current) increased by 19%, from $8431 million on March 31, 2024, to $10006 million on March 31, 2025[14] - Adjusted EBITDA margin increased from 145% to 190%[23] Unit Economics - Sales per submission decreased by 15%, from $856 in Q1 2024 to $724 in Q1 2025[16] - Direct operating cost per submission improved by 18%, decreasing from $640 in Q1 2024 to $522 in Q1 2025[16] Non-GAAP Measures - The company uses non-GAAP financial measures like EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin to evaluate business performance[7] - Adjusted EBITDA is calculated by adjusting EBITDA for items like severance costs, share-based compensation, professional services, operating lease impairment, and legal fees[7, 23]

Financial Performance - First quarter 2025 net revenues reached $221.0 million, a 19.1% increase from $185.6 million in the prior year period[4] - The net loss for the first quarter 2025 was $9.8 million, reflecting a 54.2% improvement compared to a net loss of $21.3 million in the prior year period[4] - Adjusted EBITDA for the first quarter 2025 was $42.1 million, a 56.4% increase from $26.9 million in the prior year period[4] - Net revenues for Q1 2025 reached $220,972,000, a 19.1% increase from $185,600,000 in Q1 2024[19] - The company reported a net loss of $9,786,000 for Q1 2025, an improvement of 54.2% compared to a net loss of $21,346,000 in Q1 2024[19] - Adjusted EBITDA for Q1 2025 was $42,060,000, compared to $26,894,000 in Q1 2024, reflecting a significant increase[20] - The net income (loss) margin improved to (4.4)% in Q1 2025, compared to (11.5)% in Q1 2024[20] Operational Metrics - Submissions in the first quarter 2025 totaled 303,026, marking a 40.2% increase from 216,148 submissions in the prior year period[4] - The number of submissions increased by 40.2%, reaching 303,026 in Q1 2025, compared to 216,148 in Q1 2024[24] - Sales per submission decreased to $724 in Q1 2025, down 15.4% from $856 in Q1 2024[24] - Direct operating cost per submission improved to $522, an 18.4% decrease from $640 in the prior year period[4] - Direct operating cost per submission improved to $522 in Q1 2025, a reduction of 18.4% from $640 in Q1 2024[24] Revenue Sources - The company experienced a significant increase in commission revenue, which rose to $167,109,000 from $79,733,000 year-over-year[22] - Commissions receivable - current decreased to $207,443,000 as of March 31, 2025, down from $320,399,000 at the end of 2024[23] Strategic Initiatives - GoHealth launched GoHealth Protect, expanding its product offerings into guaranteed acceptance life insurance[4] - The company aims to enhance cash flow generation and reduce acquisition costs through the scaling of the new life insurance offering[3] - Investments in high-return initiatives are expected to drive continued momentum in future quarters[3] - The company is focused on refining its platform and technology to improve consumer experience and outcomes[3] - GoHealth's proprietary technology platform leverages machine-learning algorithms to match health plans to consumer needs[7]

Core Insights - GoHealth, Inc. reported strong financial results for Q1 2025, highlighting significant growth in revenue and improved operational metrics [1][3][6] - The company launched GoHealth Protect, expanding its product offerings to include guaranteed acceptance life insurance, aiming to enhance customer relationships and unit economics [3][6] Financial Performance - Q1 2025 net revenues reached $221.0 million, a 19.1% increase from $185.6 million in Q1 2024 [6][19] - The net loss for Q1 2025 was $9.8 million, showing a 54.2% improvement compared to a net loss of $21.3 million in the prior year [6][19] - Adjusted EBITDA for Q1 2025 was $42.1 million, a 56.4% increase from $26.9 million in Q1 2024 [6][19] - The number of submissions increased to 303,026, a 40.2% rise from 216,148 submissions in the same period last year [6][26] Operational Metrics - Direct Operating Cost per Submission improved to $522, an 18.4% decrease from $640 in Q1 2024 [6][26] - The company reported a total operating expense of $214.3 million, a 13.0% increase from $189.6 million in the prior year [19] - The Adjusted EBITDA Margin for Q1 2025 was 19.0%, compared to 14.5% in Q1 2024 [20][19] Product Development - The launch of GoHealth Protect aims to diversify the company's offerings and improve customer engagement [3][6] - The new product suite is expected to enhance cash flow generation and reduce customer acquisition costs as it scales [3][6]

Core Viewpoint - GoHealth, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following a False Claims Act complaint filed by the U.S. Department of Justice against several health insurance companies, including GoHealth [1][2]. Group 1: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against GoHealth on behalf of its stockholders [1]. - The DOJ's complaint alleges that from 2016 to at least 2021, GoHealth and other insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments into Medicare Advantage plans [2]. Group 2: Stock Market Impact - Following the announcement of the DOJ's lawsuit, GoHealth's stock price dropped by $1.09 per share, representing a decline of 10.35%, closing at $9.44 per share on May 1, 2025 [2].